Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA Warning letter to Glenmark Facility at Pithampur (FEI 3008565058), cited cGMP violations at multiple
USFDA 483 issued to Glenmark Pharma’s Pithampur facility (FEI: 3008565058) in India flagged critical deviations
The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Aspen Biopharma Labs
FDA issued Warning letter to two Chinese API manufacturers following for cGMP violations including failing
Authored by: Venkiteswaran.T.K, SubrangshuChourdhary, Srinivas Churya, Satish Reddy, Sanjeev Kumar Singh Aarti Drugs API facility in Tarapur, India
With contributions from: Venkiteswaran.T.K; Satish Reddy; Shashank Sharma; Srinivas Churya; Subrangshu Choudhary The USFDA inspection
In May 2023, Sun Pharma initiated recall of two lots of antidepressant drug Bupropion Hydrochloride
